Multiple treatment options—topical therapies, oral drugs, phototherapy, and biologics—are available to treat psoriasis. In particular, the approval of biologics other than TNF-α inhibitors (Almirall’s Ilumetri, Biotech’s Stelara, Eli Lilly’s Taltz, Jansenn’s Tremfya, Leo Pharma’s Kyntheum, Novartis’s Cosentyx) in recent years has helped advance psoriasis treatment and further expand physicians’ treatment armamentarium, especially for moderate to severe disease.
Current Treatment: Physician Insights probes current and future use of topical agents, phototherapy, and systemic therapies in mild, moderate, and severe patients in EU5. It extensively probes use of approved biologics and includes patient share, line of therapy, drivers of treatment selection, and barriers to broader usage.It also looks into how psoriasis is being treated in the EU5 today, as well as the factors behind those treatment decisions.
Our new Current Treatment: Physician Insights offering provides deep insights, with real-world evidence wherever possible.
- Which patients are being prescribed which treatments?
- What is the sequencing of treatment for psoriasis?
- What do physicians report as recent and anticipated changes in their treatment practices?
- What are the dermatologist-reported factors determining current prescribing patterns and recent/anticipated changes?
Markets covered: France, Germany, Italy, Spain, United Kingdom
Primary research: Survey of 251 dermatologists in the EU5 fielded in July 2020.
Key companies: AbbVie, Almirall, Amgen, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, UCB
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
- Psoriasis - Current Treatment - Detailed, Expanded Analysis (EU5)
- Current Treatment_Physician Insights_Psoriasis_EU5_September_2020
Author(s): Mohit Nasa, MBA
Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis.
He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.